Additionally, applying these inhibitors is limited to a small number of tumors with KRAS mutation, i.e., in 13 % of KRAS mutated NSCLCs, in 1 to 3 % of KRAS mutated colorectal cancers and in 1 to 2 % of KRAS mutated pancreatic cancers [128]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.